ASX Share rice
Fri 14 May 2021 - 07:26:pm (Sydney)

CAN Share Price

CANN GROUP LIMITEDCANPharmaceuticals, Biotechnology & Life Sciences

CAN Company Information


Cann Group Limited




Drug Manufacturers-Specialty & Generic

GIC Industry:


GIC Sub Industry:



Walter & Eliza Hall Inst. of Medical Res Bundoora VIC Australia 3083


61 3 9095 7088

Chief Exec. Officer:

Mr. Peter Crock M.B.A., MBA

Chief Financial Officer:

Mr. Greg Bullock

Chief Operating Officer:

Mr. Shane Duncan

Chief Projects & Information Officer:

Mr. Geoff Aldred

Chief Compliance Officer & Company Sec.:

Ms. Geraldine T. Farrell B.Sc., FCIS, L.L.B., L.L.M.

Head of Investor Relations:

Mr. Clive Fanning

Head of Legal:

Mr. Steven Notaro

Company Overview:

Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, processing, packaging, and distribution and supply of medicinal cannabis for various diseases and medical conditions in Australia. The company was founded in 2014 and is based in Bundoora, Australia.

CAN Share Price Information

Shares Issued:


Market Capitalisation:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Profit Margin:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


CAN CashFlow Statement

CashFlow Date:




Change To Liabilities:


Total Cashflow From Investing Activities:


Net Borrowings:


Net Income:


Total Cash From Operating Activities:




Change To Inventory:


Change To Account Receivables:


Sale Purchase Of Stock:


Capital Expenditures:


CAN Income Statement

Income Date:


Income Before Tax:


Net Income:


Gross Profit:


Operating Income:


Interest Expense:


Total Revenue:


Cost Of Revenue:


CAN Balance Sheet

Balance Sheet Date:


Intangible Assets:


Total Liabilities:


Total Stockholder Equity:


Total Assets:


Common Stock:


Other Current Assets:


Retained Earnings:


Other Assets:




Total Current Liabilities:


Property - Plant & Equipment:


Net Tangible Assets:


Long-Term Investments:


Total Current Assets:


Long-Term Debt:


Net Receivables:


Short-Term Investments:




Accounts Payable:


Non Currrent Assets (Other):


Short-Term Investments:


Non Current Liabilities Total:


CAN Share Price History

CAN News

23 Feb, 2021
We feel now is a pretty good time to analyse Cann Group Limited's ( ASX:CAN ) business as it appears the company may be...
16 Feb, 2021
Satipharm sale reinforces Harvest One's strategic realignment and transition to become a cannabis-focused Consumer Packaged Goods ("CPG") companyHarvest One has the opportunity to continue to represent Satipharm-branded products in North AmericaVancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - Harvest One Cannabis Inc. (TSXV: HVT) (OTCQB: HRVOF) ("Harvest One" or the "Company"), a uniquely positioned, cannabis-infused CPG leader, announced today that it has entered into a definitive sale agreement (the "Agreement") to sell all ...
25 Nov, 2020
One thing we could say about the covering analyst on Cann Group Limited (ASX:CAN) - they aren't optimistic, having...
14 Oct, 2020
Aurora Cannabis Inc. (NYSE: ACB) opted to part ways with Australia-based Cann Group.The Canadian cannabis company sold its 12% stake via off-market trades "to a small number of undisclosed buyers" on Friday, Oct 9, after the market closed.Aurora is also selling its assets in Uruguay, per MJ Biz Daily. Alejandro Antalich, the CEO overseeing the company's South American operations, exited the company, the report continued.Both developments come on the heels of Aurora's fourth-quarter earnings report, which was released Monday.During the last fiscal year, the company lost over CA$3.3 billion ($2.5 billion).In addition, its impairment loss amounted to CA$37.2 million ($28.2 million) on its Cann Group position for the fiscal year. In the last year, the impairment charge was CA$18.2 million.Aurora spokeswoman Michelle Lefler told the cannabis business news outlet that they "continue to see growth potential in this important market and will maintain active relationships with key distribution partners to enhance the availability of Aurora's portfolio of leading, high-quality medical cannabis."As a part of its "business transformation plan," executive chair Michael Singer recently noted that the company has been "building the infrastructure and capabilities necessary for a successful and diversified business."Singer was appointed to the role after serving as the company's interim CEO for over six months.Lefler further explained that Aurora's primary focus is on its "core markets," including the medical and recreational market in Canada, the development of international medical markets, and the CBD market in the U.S. on which the company debuted in May.Courtesy imageSee more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Cannabis Movers & Shakers: Aurora, One World Pharma * Aurora Cannabis Touts 'Business Transformation Plan,' Confirms New CEO And Financial Update(C) 2020 Benzinga does not provide investment advice. All rights reserved.
07 Jul, 2020
Cann Group Limited (ASX:CAN) shareholders might be concerned after seeing the share price drop 15% in the last month...